GlassScriptPhysician profile
Carly Dunn
NPI 1578025615
$7,742.40
in general payments reported to CMS, 2019-2025
25 companies · $3,965 in 2025
The $3,965 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $341 · 2024: $3,436 · 2025: $3,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,363 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,362.79 |
| Education | $379.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $2,070.51 | 2024-2025 | Daxxify, Daxi |
| Abbvie INC. | $817.45 | 2023-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $752.05 | 2024-2025 | Tremfya |
| Leo Pharma INC. | $684.52 | 2024-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $568.50 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $514.82 | 2023-2025 | Ilumya |
| Galderma Laboratories, L.P. | $412.10 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $295.51 | 2023-2025 | Opzelura |
| Journey Medical Corporation | $237.48 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $222.46 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $161.94 | 2024-2025 | Taltz, Ebglyss |
| Ucb, INC. | $149.91 | 2025 | Bimzelx |
| Pfizer INC. | $121.03 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $114.60 | 2023-2024 | Sotyktu |
| Medtronic, INC. | $101.83 | 2024 | V-Loc 180 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $86.89 | 2025 | Seysara |
| Amgen INC. | $79.97 | 2024-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.62 | 2024-2025 | Cabtreo |
| Novartis Pharmaceuticals Corporation | $72.27 | 2025 | |
| Arcutis Biotherapeutics, INC. | $69.21 | 2025 | Zoryve |
| Organon LLC | $36.51 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.44 | 2024 | Spevigo |
| Vertex Pharmaceuticals Incorporated | $27.10 | 2024 | |
| Verrica Pharmaceuticals INC. | $21.42 | 2025 | Ycanth |
| Mayne Pharma Commercial LLC | $19.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.